Former President and Chief Operating Officer · LIGAND PHARMACEUTICALS INC (LGND)

Matthew Korenberg

A named executive officer of LIGAND PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,587,288

Salary $549,912Stock awards $1,801,880

FY2022: $6,542,545

2nd of 4 named executive officers at Ligand Pharmaceuticals by FY2023 total.

4 named officers on file for LIGAND PHARMACEUTICALS, FY2023

Matthew Korenberg’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 21 equity grants, each cited to its filing
  • LGND’s disclosed peer group of 44 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LIGAND PHARMACEUTICALS’s whole pay program stands against its peers

  • LIGAND PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LGND→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2025 (DEF 14A).

Free

Get Matthew Korenberg’s full pay file as a PDF — free

More than this page: up to 10 years of Matthew’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Matthew Korenberg compensation by year

LIGAND PHARMACEUTICALS Summary Compensation Table · all 8 fiscal years held
In US dollars, as LIGAND PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$378,750$403,438$428,438$466,667$482,833$497,297$519,858$549,912
Bonus$0$30,000$0$0$0$0$0$0
Stock awards$664,015$736,550$1,077,560$1,466,580$1,150,224$4,890,114$2,691,809$1,801,880
Option awards$797,704$768,266$921,591$1,445,555$1,206,821$1,082,118$3,089,749$953,640
Non-equity incentive$118,500$242,063$235,641$186,667$265,558$248,649$234,229$274,956
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$7,872$5,400$5,400$5,734$5,700$7,300$6,900$6,900
Total$1,966,841$2,185,717$2,668,630$3,571,203$3,111,136$6,725,479$6,542,545$3,587,288

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 22, 2025, accession 0000886163-25-000025, and prior-year filings. Open the filing on EDGAR.

How this page was built: the LIGAND PHARMACEUTICALS INC filed document, accession 0000886163-25-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2025.

$2.0M
$2.2M
$2.7M
$3.6M
$3.1M
$6.7M
$6.5M
$3.6M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU47,505$3,173,334—
PSU8,454$564,727—
Option1,065—$68.74
Option5,482—$103.42
Option41,016—$52.84
Option25,967—$67.03
Option7,834—$55.75
Option30,000—$63.62

Per the Outstanding Equity Awards at Fiscal Year-End table in LIGAND PHARMACEUTICALS INC's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

LIGAND PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Todd DavisChief Executive Officer$6,216,518
Matthew Korenberg · this pageFormer President and Chief Operating Officer$3,587,288
Tavo EspinozaChief Financial Officer$2,450,631
Andrew ReardonChief Legal Officer and Secretary$2,337,081

Board service

LIGAND PHARMACEUTICALS board · FY2023

How this board is paid

Company policy: LIGAND PHARMACEUTICALS pays directors a $42,000 cash retainer and $375,000 in RSUs and Options. As stated in LIGAND PHARMACEUTICALS's FY2025 proxy.

The full LIGAND PHARMACEUTICALS compensation record

free company brief

This page is one person within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the LIGAND PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LIGAND PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew Korenberg's compensation dossier · One-time report. No refunds.